SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase I for Liver Cancer.
The drug candidate is administered by intratumoral and intravenous routes.It is a genetically modified strain of Salmonella enterica, serotype typhimurium that expresses L-Methioninase, It acts by ...
Bacterial immune evasion is the process by which bacteria avoid and antagonize the bacterial host response, which is mediated by the host's immune system. Here, the authors show that vaginal ...
Future Microbiol. 2009;4(2):223-240.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback